Immunex pilot development plant
Executive Summary
Firm is building a $4 mil., 10,000 sq. ft. facility in Seattle to produce pharmaceuticals for clinical trials and expanded research. Immunex said the plant will allow it to refine production techniques which can be applied to a commercial scale manufacturing plant that Kodak and Immunex intend to construct in 1988. The pilot plant is owned by Immunex/Kodak joint venture Immunology Ventures.